Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul 9;10(14):e34345.
doi: 10.1016/j.heliyon.2024.e34345. eCollection 2024 Jul 30.

Nintedanib for the treatment of symptomatic radiation pneumonitis. A Case Report

M E Kuipers  1 , K C J Van Doorn-Wink  2 , P E Postmus  1
Affiliations
Case Reports

Nintedanib for the treatment of symptomatic radiation pneumonitis. A Case Report

M E Kuipers et al. Heliyon. .

Abstract

Radiation induced pneumonitis is a common side effect of thoracic radiotherapy. We report a case of a patient diagnosed with symptomatic radiation pneumonitis and a serious contra-indication for corticosteroids. For that reason, the patient was treated with nintedanib instead. After several weeks of treatment her symptoms and chest CT improved significantly. This case shows that nintedanib might be an effective treatment of radiation pneumonitis if corticosteroids are contra-indicated.

Keywords: Case report; NSCLC; Nintedanib; Radiation pneumonitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Representative images of chest CT showing the development and recovery of radiation pneumonitis Description: Text CT images of the chest A) in April, just after the start of durvalumab and after completion of chemoradiotherapy with no signs of radiation pneumonitis and B) in August 2022, showing severe radiation pneumonitis with breathing artefacts due to severe dyspnea, and C) in November 2022, showing partial recovery of the consolidations.
See this image and copyright information in PMC

References

    1. Hanania A.N., Mainwaring W., Ghebre Y.T., Hanania N.A., Ludwig M. Radiation-induced lung injury: assessment and management. Chest. 2019;156(1):150–162. doi: 10.1016/j.chest.2019.03.033. - DOI - PMC - PubMed
    1. Dy G.K., Prasad D., Kumar P., Attwood K., Adjei A.A. A phase 2 randomized, double-blind, placebo-controlled study evaluating nintedanib versus placebo as prophylaxis against radiation pneumonitis in patients with unresectable NSCLC undergoing chemoradiation therapy. J. Thorac. Oncol. 2021;16(3):e19–e20. doi: 10.1016/j.jtho.2020.11.019. - DOI - PubMed
    1. Roberti G., Oddone F., Agnifili L., et al. Steroid-induced glaucoma: epidemiology, pathophysiology, and clinical management. Surv. Ophthalmol. 2020;65(4):458–472. doi: 10.1016/j.survophthal.2020.01.002. - DOI - PubMed
    1. Flaherty K.R., Wells A.U., Cottin V., et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 2019;381(18):1718–1727. doi: 10.1056/nejmoa1908681. - DOI - PubMed
    1. Cytlak U.M., Dyer D.P., Honeychurch J., Williams K.J., Travis M.A., Illidge T.M. Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nat. Rev. Immunol. 2022;22(2):124–138. doi: 10.1038/s41577-021-00568-1. - DOI - PubMed

Publication types

LinkOut - more resources